Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.
- INSIGHT-003 reports median overall survival of 30.9 months in 1L non-squamous NSCLC
- Majority of patients had low PD-L1 expression, a group with unmet needs
- TACTI-004 Phase III trial stopped after failing to show superiority over placebo
- Preliminary immune data reveal differing activation profiles between trials
- Root cause analysis of TACTI-004 ongoing with results due Q3 2026
INSIGHT-003 Delivers Encouraging Survival Data in Challenging NSCLC Subset
Immutep Limited (ASX:IMM, NASDAQ: IMMP) has unveiled mature overall survival (OS) data from its investigator-initiated INSIGHT-003 Phase I trial, showing a median OS of 30.9 months in patients with first-line non-squamous non-small cell lung cancer (NSCLC). This figure notably outpaces the 22.0 months median OS reported in historical registrational trials of pembrolizumab combined with chemotherapy, despite nearly 92% of INSIGHT-003 participants exhibiting low or no PD-L1 expression, a subgroup traditionally associated with poorer outcomes.
The trial enrolled 51 evaluable patients, with 47 having Tumour Proportion Scores (TPS) under 50%. The survival benefit was consistent across this low PD-L1 cohort, reinforcing efti’s potential to enhance anti-tumour immune responses where standard PD-1 inhibitors often falter. Patients with higher PD-L1 expression (TPS ≥50%) showed an even longer median OS of 37.8 months, though this group was small (n=4).
TACTI-004 Phase III Trial Discontinued After Futility Analysis
In stark contrast, Immutep’s pivotal TACTI-004 Phase III trial in first-line NSCLC was halted earlier this year following an independent futility review. The interim analysis revealed an objective response rate (ORR) of 42.9% in the efti arm versus 55.1% in the placebo arm, with no subgroup showing superiority for efti. This outcome led to the trial’s discontinuation and a strategic reassessment of efti’s clinical development in NSCLC.
Comparatively, the INSIGHT-003 trial reported a higher ORR of 62.7%, despite its challenging patient population. The divergence between these trials has prompted a comprehensive root cause analysis, with Immutep investigating potential factors including manufacturing and immune response variations. The company is collaborating with partners such as Dr. Reddy’s and WuXi Biologics to understand these discrepancies.
Immune Monitoring Points to Distinct Activation Profiles
Preliminary immune monitoring data from TACTI-004 indicate that patients treated with efti exhibited a markedly different immune activation profile compared to previous studies, including INSIGHT-003 and five earlier trials involving nearly 600 patients. This assessment is based on analyses of absolute lymphocyte counts and circulating monocytes, suggesting that efti’s immune engagement in TACTI-004 may have deviated from expected patterns.
These findings, while preliminary, are critical as they may explain the lack of efficacy observed and guide future development decisions. Immutep expects to release further results from this root cause analysis in the third quarter of 2026.
Efti’s Mechanism and Regulatory Status
Eftilagimod alfa (efti) is an MHC Class II agonist that activates antigen-presenting cells, stimulating both innate and adaptive immunity against cancer. Its safety profile has allowed combinations with PD-1 inhibitors like pembrolizumab (KEYTRUDA), chemotherapy, and radiotherapy across several solid tumours. Notably, efti has received Fast Track designation from the FDA for first-line head and neck squamous cell carcinoma and NSCLC, underscoring its potential clinical value.
CEO Marc Voigt emphasised the encouraging survival data from INSIGHT-003, particularly in patients with low PD-L1 expression, while acknowledging the need to fully understand the TACTI-004 results before charting the next steps for efti.
Bottom Line?
Immutep’s robust INSIGHT-003 survival data contrast sharply with the halted TACTI-004 trial, leaving the company at a critical juncture pending root cause insights due later this year.
Questions in the middle?
- What specific factors underlie the divergent immune activation profiles observed between TACTI-004 and earlier efti studies?
- How will the root cause analysis influence Immutep’s regulatory strategy and future clinical trial designs for efti?
- Can efti’s promising results in low PD-L1 NSCLC patients be replicated or expanded in larger, controlled studies?